TIGIT+ macrophages were also looked at in leukemia, in which the leukemia-associated macrophages (LAM) co-expressing TIGIT, TIM3, and LAG3 were identified as immunosuppressive M2 responsive to in vitro TIGIT blockade therapy that polarizes the M2 toward the M1 phenotype and improves phagocytosis of the CD47 expressing tumor cells (172, 173). This evidence concerns the gene HAVCR2 and neoplasm.